Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

NCT05517421 is registered in ClinicalTrials.gov with Immunovant Sciences GmbH as lead sponsor.

NCT NCT05517421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05517421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Lead sponsor
Immunovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
November 23, 2022
Completion date
November 18, 2025
Enrollment
114 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease